This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Myrthue, A. Articles by Beer, T. M. PubMed PubMed Citation Articles by Myrthue, A. Articles by Beer, T. M.

The Iroquois Homeobox Gene 5 Is Regulated by 1,25-Dihydroxyvitamin D₃ in Human Prostate Cancer and Regulates Apoptosis and the Cell Cycle in LNCaP Prostate Cancer Cells

Authors' Affiliation: Division of Hematology and Medical Oncology and OHSU Cancer Institute, Oregon Health and Science University, Portland, Oregon

Requests for reprints: Tomasz M. Beer, Division of Hematology and Medical Oncology, Oregon Health and Science University, CH-14R, 3303 SW Bond Avenue, Portland, OR 97239. Phone: 503-494-0365; Fax: 503-494-6197; E-mail: beert{at}ohsu.edu.

1,25-Dihydroxyvitamin D₃ [1,25(OH)₂D₃], the most active metabolite of vitamin D₃, has significant antitumor activity in a broad range of preclinical models of cancer. In this study, we show that the Iroquois homeobox gene 5 (Irx5) is down-regulated by 1,25(OH)₂D₃ in human prostate cancer samples from patients randomly assigned to receive weekly high-dose 1,25(OH)₂D₃ or placebo before radical prostatectomy. Down-regulation of Irx5 by 1,25(OH)₂D₃ was also shown in the human androgen-sensitive prostate cancer cell line LNCaP and in estrogen-sensitive MCF-7 breast cancer cells. Knockdown of Irx5 by RNA interference showed a significant reduction in LNCaP cell viability, which was accompanied by an increase in p21 protein expression, G₂-M arrest, and an increase in apoptosis. The induced apoptosis was partially mediated by p53, and p53 protein expression was increased as a result of Irx5 knockdown. Cell survival was similarly reduced by Irx5 knockdown in the colon cancer cell line HCT 116 and in MCF-7 breast cancer cells, each being derived from clinical tumor types that seem to be inhibited by 1,25(OH)₂D₃. Overexpression of Irx5 led to a reduction of p21 and p53 expression. This is the first report that Irx5 is regulated by 1,25(OH)₂D₃ in humans and the first report to show that Irx5 is involved in the regulation of both the cell cycle and apoptosis in human prostate cancer cells. Irx5 may be a promising new therapeutic target in cancer treatment.